JP2021528469A5 - - Google Patents
Info
- Publication number
- JP2021528469A5 JP2021528469A5 JP2020572994A JP2020572994A JP2021528469A5 JP 2021528469 A5 JP2021528469 A5 JP 2021528469A5 JP 2020572994 A JP2020572994 A JP 2020572994A JP 2020572994 A JP2020572994 A JP 2020572994A JP 2021528469 A5 JP2021528469 A5 JP 2021528469A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- dihydro
- oxo
- naphthyridine
- piperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862690444P | 2018-06-27 | 2018-06-27 | |
| US62/690,444 | 2018-06-27 | ||
| PCT/US2019/039131 WO2020006016A1 (en) | 2018-06-27 | 2019-06-26 | Naphthyridinone compounds useful as t cell activators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021528469A JP2021528469A (ja) | 2021-10-21 |
| JP2021528469A5 true JP2021528469A5 (enExample) | 2023-07-06 |
| JP7373512B2 JP7373512B2 (ja) | 2023-11-02 |
Family
ID=67297314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020572994A Active JP7373512B2 (ja) | 2018-06-27 | 2019-06-26 | Ｔ細胞アクティベーターとして有用なナフチリジノン化合物 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11866430B2 (enExample) |
| EP (1) | EP3814347B1 (enExample) |
| JP (1) | JP7373512B2 (enExample) |
| KR (1) | KR102804324B1 (enExample) |
| CN (1) | CN112585139B (enExample) |
| AU (1) | AU2019291792B2 (enExample) |
| BR (1) | BR112020026568A2 (enExample) |
| CA (1) | CA3104647A1 (enExample) |
| CY (1) | CY1126179T1 (enExample) |
| DK (1) | DK3814347T3 (enExample) |
| EA (1) | EA202190137A1 (enExample) |
| ES (1) | ES2950007T3 (enExample) |
| FI (1) | FI3814347T3 (enExample) |
| HR (1) | HRP20230627T1 (enExample) |
| HU (1) | HUE062412T2 (enExample) |
| IL (1) | IL279730B2 (enExample) |
| LT (1) | LT3814347T (enExample) |
| MX (1) | MX2020013373A (enExample) |
| PL (1) | PL3814347T3 (enExample) |
| PT (1) | PT3814347T (enExample) |
| RS (1) | RS64285B1 (enExample) |
| SG (1) | SG11202012973RA (enExample) |
| SI (1) | SI3814347T1 (enExample) |
| SM (1) | SMT202300170T1 (enExample) |
| WO (1) | WO2020006016A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| EP4065584A1 (en) | 2019-11-28 | 2022-10-05 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021105115A1 (en) | 2019-11-28 | 2021-06-03 | Bayer Aktiengesellschaft | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| US12478621B2 (en) | 2019-11-28 | 2025-11-25 | Deutsches Krebsforschungszentrum | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| WO2021127554A1 (en) * | 2019-12-19 | 2021-06-24 | Bristol-Myers Squibb Company | Combinations of dgk inhibitors and checkpoint antagonists |
| JP7677976B2 (ja) * | 2019-12-23 | 2025-05-15 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔ細胞アクティベーターとして有用な置換ヘテロアリール化合物 |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| CA3162979A1 (en) * | 2019-12-23 | 2021-07-01 | Upender Velaparthi | Substituted piperazine derivatives useful as t cell activators |
| IL294148A (en) | 2019-12-23 | 2022-08-01 | Bristol Myers Squibb Co | Substituted quinazolinyl compounds are useful as t-cell activators |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| CA3180670A1 (en) * | 2020-04-24 | 2021-10-28 | Bayer Aktiengesellschaft | Substituted aminothiazoles as dgkzeta inhibitors for immune activation |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| JP7604067B2 (ja) * | 2020-11-26 | 2024-12-23 | エルジー・ケム・リミテッド | ジアシルグリセロールキナーゼ阻害剤としての複素環化合物及びその用途 |
| AU2021400725A1 (en) | 2020-12-16 | 2023-08-03 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| KR20230165771A (ko) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법 및 dgk 억제제의 조합 |
| MX2023014762A (es) * | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| EP4359413A1 (en) * | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117355531A (zh) * | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| JP7651018B2 (ja) * | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| WO2023122777A1 (en) * | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| CN118946556A (zh) * | 2022-02-01 | 2024-11-12 | 阿维纳斯运营公司 | Dgk靶向化合物及其用途 |
| IL315015A (en) | 2022-03-01 | 2024-10-01 | Insilico Medicine Ip Ltd | Diacylglycerol kinase (DGK) alpha inhibitors and their uses |
| WO2023165528A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023165525A1 (en) * | 2022-03-01 | 2023-09-07 | Insilico Medicine Ip Limited | Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof |
| WO2023184327A1 (en) * | 2022-03-31 | 2023-10-05 | InventisBio Co., Ltd. | Kinase inhibitors, preparation methods and uses thereof |
| CN119998295A (zh) | 2022-06-08 | 2025-05-13 | 因赛特公司 | 作为dgk抑制剂的三环三唑并化合物 |
| US12600723B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| US12600722B2 (en) | 2022-07-18 | 2026-04-14 | Incyte Corporation | Tetracyclic compounds as DGK inhibitors |
| WO2024026076A2 (en) * | 2022-07-29 | 2024-02-01 | Septerna, Inc. | Substituted 3,4-dihydroquinolinone inhibitors of tshr |
| US20260049076A1 (en) | 2022-08-09 | 2026-02-19 | Bristol-Myers Squibb Company | Tertiary Amine Substituted Bicyclic Compounds Useful as T Cell Activators |
| KR20250061756A (ko) | 2022-09-08 | 2025-05-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 요법과 연속적 또는 간헐적 dgk 억제제 투여의 조합 |
| TW202436351A (zh) | 2023-02-06 | 2024-09-16 | 德商拜耳廠股份有限公司 | Ccr8抗體及dgk抑制劑之組合 |
| WO2025030002A2 (en) * | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025061020A1 (zh) * | 2023-09-21 | 2025-03-27 | 楚浦创制（武汉）医药科技有限公司 | 苯并五元杂环衍生物及其制备方法与应用、药物组合物 |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| CA2489560A1 (en) | 2002-06-27 | 2004-01-08 | Schering Aktiengesellschaft | Substituted quinoline ccr5 receptor antagonists |
| GB0230018D0 (en) | 2002-12-23 | 2003-01-29 | Syngenta Ltd | Fungicides |
| TW200418829A (en) | 2003-02-14 | 2004-10-01 | Avanir Pharmaceutics | Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| WO2004087880A2 (en) | 2003-03-26 | 2004-10-14 | Bayer Pharmaceuticals Corporation | Compounds and their use to treat diabetes and related disorders |
| GB0316915D0 (en) | 2003-07-18 | 2003-08-20 | Glaxo Group Ltd | Compounds |
| CA2533626A1 (en) | 2003-07-22 | 2005-02-03 | Janssen Pharmaceutica, N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
| JP2007503388A (ja) | 2003-08-22 | 2007-02-22 | アバニール・ファーマシューティカルズ | マクロファージ遊走阻止因子の阻害剤としての置換ナフチリジン誘導体、およびヒト疾患の治療におけるそれらの使用 |
| US7381401B2 (en) | 2004-01-08 | 2008-06-03 | The University Of Chicago | T cell anergy is reversed by active Ras and regulated by diacylglycerol kinase |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| DK1879573T3 (da) | 2005-05-10 | 2013-02-25 | Incyte Corp | Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| GB0605689D0 (en) | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic compounds |
| JP2007308402A (ja) | 2006-05-17 | 2007-11-29 | Sumitomo Chemical Co Ltd | シンナモイル化合物及びその用途 |
| JP2007308441A (ja) | 2006-05-22 | 2007-11-29 | Sumitomo Chemical Co Ltd | 含複素環化合物及びその用途 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| CA2663057C (en) | 2006-09-19 | 2015-12-08 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| WO2009073620A2 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics | Ido inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| WO2010042489A2 (en) | 2008-10-06 | 2010-04-15 | Emory University | Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| US20110319416A1 (en) | 2009-01-28 | 2011-12-29 | Emory University | Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| WO2012009649A1 (en) | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| US9133164B2 (en) | 2011-04-13 | 2015-09-15 | Innov88 Llc | MIF inhibitors and their uses |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| US9006257B2 (en) | 2012-02-09 | 2015-04-14 | Glenmark Pharmaceuticals S.A. | Bicyclic compounds as mPGES-1 inhibitors |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014039513A2 (en) | 2012-09-04 | 2014-03-13 | The Trustees Of The University Of Pennsylvania | Inhibition of diacylglycerol kinase to augment adoptive t cell transfer |
| AR093512A1 (es) * | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados heterociclicos como moduladores de la actividad de cinasas |
| AU2016245864C1 (en) | 2015-04-10 | 2021-09-09 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| WO2017177037A1 (en) | 2016-04-06 | 2017-10-12 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| JOP20190086A1 (ar) * | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| GB201700814D0 (en) | 2017-01-17 | 2017-03-01 | Liverpool School Tropical Medicine | Compounds |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US12187687B2 (en) | 2017-06-26 | 2025-01-07 | University Of Virginia Patent Foundation | Compositions and uses thereof |
-
2019
- 2019-06-26 SG SG11202012973RA patent/SG11202012973RA/en unknown
- 2019-06-26 WO PCT/US2019/039131 patent/WO2020006016A1/en not_active Ceased
- 2019-06-26 CA CA3104647A patent/CA3104647A1/en active Pending
- 2019-06-26 DK DK19740166.4T patent/DK3814347T3/da active
- 2019-06-26 PT PT197401664T patent/PT3814347T/pt unknown
- 2019-06-26 BR BR112020026568-3A patent/BR112020026568A2/pt not_active Application Discontinuation
- 2019-06-26 EP EP19740166.4A patent/EP3814347B1/en active Active
- 2019-06-26 PL PL19740166.4T patent/PL3814347T3/pl unknown
- 2019-06-26 IL IL279730A patent/IL279730B2/en unknown
- 2019-06-26 EA EA202190137A patent/EA202190137A1/ru unknown
- 2019-06-26 FI FIEP19740166.4T patent/FI3814347T3/fi active
- 2019-06-26 HR HRP20230627TT patent/HRP20230627T1/hr unknown
- 2019-06-26 MX MX2020013373A patent/MX2020013373A/es unknown
- 2019-06-26 KR KR1020217002232A patent/KR102804324B1/ko active Active
- 2019-06-26 SM SM20230170T patent/SMT202300170T1/it unknown
- 2019-06-26 SI SI201930549T patent/SI3814347T1/sl unknown
- 2019-06-26 CN CN201980055153.7A patent/CN112585139B/zh active Active
- 2019-06-26 US US17/254,914 patent/US11866430B2/en active Active
- 2019-06-26 ES ES19740166T patent/ES2950007T3/es active Active
- 2019-06-26 JP JP2020572994A patent/JP7373512B2/ja active Active
- 2019-06-26 LT LTEPPCT/US2019/039131T patent/LT3814347T/lt unknown
- 2019-06-26 RS RS20230468A patent/RS64285B1/sr unknown
- 2019-06-26 HU HUE19740166A patent/HUE062412T2/hu unknown
- 2019-06-26 AU AU2019291792A patent/AU2019291792B2/en not_active Ceased
-
2023
- 2023-07-28 CY CY20231100377T patent/CY1126179T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230627T1 (hr) | Spojevi naftiridinona korisni kao aktivatori t ćelija | |
| JP6466433B2 (ja) | ヒト免疫不全ウイルス複製の阻害剤 | |
| CA2481012C (en) | Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors | |
| US9242991B2 (en) | Substituted fused heterocycles as c-Met tyrosine kinase inhibitors | |
| WO2020261114A1 (en) | 2,3-dihydroquinazolin compounds as nav1.8 inhibitors | |
| AU2007319209B2 (en) | Arylsulfonamide compounds | |
| IL144461A (en) | History of quinoline and quinazoline and pharmaceutical preparations containing them | |
| US10787458B2 (en) | Chiral synthesis of N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-A]pyrazines | |
| RU2005124558A (ru) | Производные 1-пропанола и 1-пропиламина и их применение в качестве глюкокортикоидных лигандов | |
| JP2017533958A5 (enExample) | ||
| RU2013105490A (ru) | Спироциклические аминовые производные в качестве модуляторов s1p | |
| CA2493667A1 (en) | Vanilloid receptor ligands and their use in treatments | |
| HK1039938A1 (zh) | 用作cetp抑制剂的4-氨基取代的-2-取代的-1，2，3，4-四氢喹啉 | |
| MXPA03003531A (es) | Derivados de heteroaril alquilo piperazina como inhibidores de la oxidacion de acidos grasos. | |
| CA2509413A1 (en) | Benzazepine derivatives for the treatment of neurological disorders | |
| EP2152672A1 (en) | Novel sulphoximine-substituted quinazoline and quinazoline derivatives as kinase inhibitors | |
| WO2016176449A1 (en) | Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators | |
| CA2871453A1 (en) | Quinazolinedione derivative | |
| CA2637597A1 (en) | Tetrahydronaphthalene derivatives, processes for preparing them and their use as anti-inflammatory agents | |
| US11993591B2 (en) | Chromen-4-one derivatives for the treatment and prophylaxis of hepatitis B virus disease | |
| US20240166622A1 (en) | Fluorinated quinoline, quinoxaline and benzo[b][1,4]oxazine derivatives as dihydroorotate dehydrogenase (dhodh) inhibitors for the treatment of cancer, autoimmune and inflammatory diseases | |
| EP1689718A1 (en) | 1-amino-isoquinoline derivatives for the treatment of diseases associated with inappropriate alk5 activity | |
| JP2023551435A (ja) | Ｂ型肝炎ウイルス感染症の処置及び予防のためのｎ置換４－（１，３－アリールオキサゾロ－２－イル）フェニル化合物 | |
| AU2021216714A1 (en) | Heterocyclic compounds as dihydroorotate dehydrogenase inhibitors | |
| KR20150075091A (ko) | 3,4-이치환된 옥사졸리디논 유도체 및 칼슘 활성화 칼륨 채널의 억제제로서 이의 용도 |